Merck & Co., Inc. has announced that Thomas H. Glocer intends to retire from the company’s Board of Directors at the 2027 Annual Meeting of Shareholders. The retirement is scheduled for May 2027 and is not related to any disagreements regarding the company’s operations, policies, or practices.

In a related leadership change, the independent members of the Board have appointed Douglas M. Baker, Jr. as the independent lead director. Mr. Baker will assume this role effective January 1, 2027, succeeding Mr. Glocer. Mr. Baker has served on the Merck Board of Directors since 2022 and brings extensive experience in corporate governance and organizational management, including a background as the former chairman and chief executive officer of Ecolab Inc. He is also a trustee of Mayo Clinic.

Rob Davis, the Chairman and Chief Executive Officer of Merck, expressed gratitude for Mr. Glocer’s service and highlighted Mr. Baker’s qualifications for the expanded role.